LeMaitre Vascular (NASDAQ:LMAT) Downgraded by BidaskClub

BidaskClub cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research note published on Wednesday, March 27th, BidAskClub reports.

Other research analysts have also recently issued research reports about the company. ValuEngine raised LeMaitre Vascular from a sell rating to a hold rating in a research report on Tuesday, December 11th. Zacks Investment Research cut LeMaitre Vascular from a hold rating to a sell rating in a research report on Thursday, December 6th. Lake Street Capital increased their price objective on LeMaitre Vascular to $27.00 and gave the stock a hold rating in a report on Wednesday, February 20th. Finally, Roth Capital reissued a neutral rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $33.29.

LeMaitre Vascular stock traded up $0.18 during trading on Wednesday, hitting $27.24. 102,760 shares of the company were exchanged, compared to its average volume of 142,113. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $41.28. The company has a market capitalization of $535.84 million, a P/E ratio of 32.43, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.24. The business had revenue of $28.39 million during the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%. On average, sell-side analysts anticipate that LeMaitre Vascular will post 0.84 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, April 5th. Shareholders of record on Friday, March 22nd were paid a $0.085 dividend. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.07. This represents a $0.34 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date was Thursday, March 21st. LeMaitre Vascular’s dividend payout ratio is currently 40.48%.

In other LeMaitre Vascular news, insider Trent G. Kamke sold 16,604 shares of the company’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $29.63, for a total value of $491,976.52. Following the transaction, the insider now directly owns 19,857 shares in the company, valued at approximately $588,362.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.30% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of LeMaitre Vascular by 2.2% during the 4th quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock valued at $61,496,000 after purchasing an additional 56,161 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,698,881 shares of the medical instruments supplier’s stock valued at $52,665,000 after purchasing an additional 25,750 shares during the last quarter. Vanguard Group Inc. increased its position in shares of LeMaitre Vascular by 5.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after purchasing an additional 66,427 shares during the last quarter. Vanguard Group Inc increased its position in shares of LeMaitre Vascular by 5.8% during the 3rd quarter. Vanguard Group Inc now owns 1,208,742 shares of the medical instruments supplier’s stock valued at $46,826,000 after purchasing an additional 66,427 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of LeMaitre Vascular by 1.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,020,116 shares of the medical instruments supplier’s stock valued at $39,519,000 after purchasing an additional 14,038 shares during the last quarter. Hedge funds and other institutional investors own 76.52% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: Cost of Equity For A Business, Investors

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.